| 831 |
Centers for Disease Control and Prevention |
Html |
en |
CDC Grand Rounds: Reducing the Burden of HPV-Associated Cancer and Disease |
This is another in a series of occasional MMWR reports titled CDC Grand Rounds. These reports are based on grand rounds presentations at CDC on high-profile issues in public health science, practice, and policy. Information about CDC Grand Rounds is available at http://www. |
| papilloma virus vaccine | 0.493764 |
| United States | 0.664529 |
| HPV vaccine introduction | 0.599547 |
| oropharyngeal cancers | 0.493781 |
| HPV vaccine | 0.931899 |
| HPV types | 0.67319 |
| vaccine efficacy | 0.505171 |
| prophylactic HPV vaccines | 0.571432 |
| Evidence-Based HPV Prevention | 0.566772 |
| vaginal intraepithelial neoplasia | 0.486325 |
| Engl J Med | 0.496612 |
| vaccine doses | 0.491907 |
| prophylactic human papillomavirus | 0.540648 |
| HPV-16/18 AS04-adjuvanted vaccine | 0.492256 |
| quadrivalent human papillomavirus | 0.547161 |
| meningococcal conjugate vaccine | 0.504259 |
| HPV vaccination coverage | 0.729851 |
| quadrivalent hpv vaccine | 0.710952 |
| vaccination coverage levels | 0.484596 |
| adolescent HPV vaccination | 0.595548 |
| cause cervical cancers | 0.483775 |
| CDC Grand Rounds | 0.483898 |
| HPV vaccination program | 0.586166 |
|
| anal intraepithelial neoplasia | 0.490417 |
| Vaccine Adverse Event | 0.504871 |
| vaccine HPV types | 0.623133 |
| human papillomavirus vaccination | 0.507733 |
| Vaccine Safety Datalink | 0.538842 |
| papillomavirus quadrivalent vaccine | 0.560537 |
| AS04-adjuvanted vaccine | 0.52012 |
| HPV disease prevention | 0.561 |
| HPV vaccines | 0.572166 |
| HPV prevalence | 0.53953 |
| HPV-associated anal cancers | 0.483178 |
| HPV Prevention | 0.571509 |
| Mucosal HPV types | 0.587967 |
| high-risk hpv | 0.566538 |
| human papillomavirus | 0.70264 |
| et al | 0.65739 |
| National HPV vaccination | 0.597633 |
| oncogenic HPV types | 0.595889 |
| HPV type distribution | 0.553905 |
| continued prophylactic efficacy | 0.498125 |
| human papillomavirus vaccine | 0.531954 |
| anal HPV infection | 0.592827 |
|
CLICK HERE |
| 6263 |
Centers for Disease Control and Prevention |
Html |
en |
FASD Competency-Based Curriculum Development Guide for Medical and Allied Health Education and Practice |
FASDs are 100% preventable if a woman does not drink alcohol during pregnancy. There is no known safe amount of alcohol to drink while pregnant. There is also no safe time during pregnancy to drink and no safe kind of alcohol. |
| list Skip | 0.306161 |
| FASD Regional Training | 0.912535 |
| sample teaching tools | 0.260796 |
| Regional Training Centers | 0.751594 |
|
| FASD Competency-Based Curriculum | 0.476535 |
| page options Skip | 0.450287 |
| fetal alcohol spectrum | 0.318919 |
| Allied Health Education | 0.315274 |
|
CLICK HERE |
| 6628 |
Centers for Disease Control and Prevention |
Html |
null |
Chemical Class - Warfare and Terrorism Agents used in acts of war or terror |
Warfare or terrorism agents are a class that includes chemicals, biological substances, radioactive materials, nuclear materials, or explosives. These agents can be used in war against enemies or to frighten groups of individuals. |
|
|
CLICK HERE |
| 8907 |
Centers for Disease Control and Prevention |
Html |
en |
MMWR - June 14, 2013, Appendix F: Management of the IUD when a Cu-IUD or an LNG-IUD User Is Found To Have Pelvic Inflammatory Disease |
Abbreviations: Cu-IUD = copper-containing IUD; IUD = intrauterine device; LNG-IUD = levonorgestrel-releasing IUD; PID = pelvic inflammatory disease. |
| date | 0.437014 |
| endorsement | 0.561909 |
| woman | 0.441979 |
| Alternate Text | 0.666649 |
| Human Services | 0.870012 |
| Superintendent | 0.451851 |
| levonorgestrel-releasing IUD | 0.76528 |
| Users | 0.435058 |
| URL | 0.439621 |
| content | 0.437674 |
| U.S. Department | 0.85994 |
| MMWR HTML versions | 0.824232 |
| MMWR readers | 0.648994 |
| character translation | 0.623627 |
| identification | 0.441122 |
| pages | 0.437639 |
| U.S. Government Printing | 0.79612 |
| MMWR paper copy | 0.82176 |
| electronic PDF version | 0.801877 |
| publication | 0.43698 |
| intrauterine device | 0.693148 |
| http://www.cdc.gov/mmwr | 0.43491 |
| format errors | 0.644424 |
| flow chart | 0.665243 |
|
| **Questions | 0.435025 |
| Health | 0.475467 |
| Contact GPO | 0.70074 |
| typeset documents | 0.650056 |
| trade names | 0.659378 |
| commercial sources | 0.659033 |
| paper copy | 0.827388 |
| official text | 0.616887 |
| pelvic inflammatory disease | 0.915637 |
| Appendix | 0.462364 |
| current prices | 0.618889 |
| copper-containing IUD | 0.765925 |
| non-CDC sites | 0.639684 |
| management | 0.442109 |
| cdc.gov | 0.434804 |
| original paper copy | 0.805104 |
| References | 0.438414 |
| organizations | 0.438001 |
| messages | 0.434991 |
| Internet | 0.438311 |
| programs | 0.437949 |
| electronic conversions | 0.628078 |
| articles | 0.436124 |
|
CLICK HERE |
| 9153 |
Centers for Disease Control and Prevention |
Html |
en |
Investigation of Hepatitis E Outbreak Among Refugees - UpperNile, South Sudan, 2012-2013 |
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. |
| acute viral hepatitis | 0.463722 |
| Jamam camp | 0.649653 |
| HEV vaccine | 0.647552 |
| symptomatic HEV infection | 0.57019 |
| HEV infections | 0.538134 |
| Jamam refugee camp | 0.451322 |
| HEV outbreak control | 0.612997 |
| AJS case-fatality rate | 0.480057 |
| CDC-Kenya Medical Research | 0.448236 |
| HEV preventive hygiene | 0.589339 |
| Yusuf Batil camp | 0.44745 |
| AJS attack rates | 0.454469 |
| pregnant women | 0.96966 |
| HEV prevention | 0.540999 |
| South Sudan Ministry | 0.747228 |
| AJS patients | 0.490798 |
| Medical Research Institute | 0.448909 |
| Maban County | 0.458181 |
| active case finding | 0.45245 |
| Yusuf Batil | 0.695766 |
| HEV infection | 0.780637 |
| World Health Organization | 0.586424 |
| Maban County refugee | 0.455854 |
| cumulative hospital CFR | 0.447555 |
| South Sudan | 0.93203 |
|
| Large HEV outbreaks | 0.646016 |
| HEV incubation period | 0.56767 |
| HEV transmission | 0.529226 |
| viral AJS etiologies | 0.4865 |
| AJS cases | 0.645874 |
| prior HEV infection | 0.581258 |
| MУЉdecins Sans FrontiУЈres | 0.53197 |
| Nations High Commissioner | 0.728402 |
| acute jaundice syndrome | 0.559416 |
| Subsequent AJS cases | 0.490155 |
| hygiene conditions | 0.44848 |
| HEV cases | 0.556766 |
| United Nations High | 0.462323 |
| Research Institute laboratory | 0.449581 |
| Global Health Protection | 0.458301 |
| newly developed HEV | 0.612704 |
| HEV genotype | 0.531702 |
| HEV outbreaks | 0.714312 |
| Yusuf Batil refugee | 0.48939 |
| past HEV infection | 0.577665 |
| Batil refugee camps | 0.477944 |
| initial AJS cases | 0.494891 |
| HEV | 0.909412 |
| series HEV vaccine | 0.573147 |
|
CLICK HERE |
| 11161 |
Centers for Disease Control and Prevention |
Html |
en |
CDC announces the formation of an external laboratory safety workgroup | Media Statement | CDC Online Newsroom | CDC |
CDC public health news, press releases, government public health news, medical and disease news, story ideas, photos. |
| CDC Director | 0.567286 |
| National Biosafety | 0.666844 |
| infectious diseases | 0.82771 |
| H5N1 influenza-containing laboratory | 0.551257 |
| environmental health | 0.589144 |
| †Certified Biological Safety | 0.558637 |
| Biological Safety Association | 0.913309 |
| Health Inspection Services | 0.567992 |
| Duke University | 0.571632 |
| American Biological Safety | 0.913345 |
| CDC BSL-2 facilities | 0.575469 |
| UTMB Institutional Biosafety | 0.593433 |
| biological laboratory safety | 0.59639 |
| Scientific Counselors | 0.556595 |
| University Safety Committee | 0.612477 |
| National Science Advisory | 0.617246 |
| Scientific Advisory Board | 0.702325 |
| Chemical Safety Program | 0.54628 |
| Livermore National Laboratory | 0.544886 |
| European Biosafety Association | 0.601389 |
| Biosafety programs | 0.557895 |
| CDC’s laboratories | 0.548999 |
| University Institutional Biosafety | 0.647126 |
| NIH’s National | 0.564529 |
| public health laboratories | 0.636247 |
|
| Public Health England | 0.557946 |
| health reference laboratory | 0.569047 |
| University Biosafety Officer | 0.639166 |
| external BSL-3 laboratory | 0.549424 |
| Infectious Diseases Laboratory | 0.565977 |
| Science Advisory Board | 0.619462 |
| Biosafety Regulations | 0.550979 |
| CDC BSL-3 facility | 0.578478 |
| Animal Biosafety Level | 0.598804 |
| National Health Security | 0.574944 |
| Regional Biocontainment Laboratory | 0.557578 |
| Institutional Biosafety Committee | 0.690222 |
| public health | 0.851519 |
| Certified Biological Safety | 0.576564 |
| CDC laboratories | 0.547595 |
| Biological Safety Professional | 0.642769 |
| Biosafety Professional | 0.556796 |
| Corporate BioSafety Programme | 0.589351 |
| Biocontainment Training Program | 0.705347 |
| laboratory safety | 0.649791 |
| Environmental Safety Office | 0.569915 |
| laboratory safety workgroup | 0.614716 |
| public health preparedness | 0.669479 |
| public health laboratory | 0.598784 |
|
CLICK HERE |
| 14269 |
Centers for Disease Control and Prevention |
Html |
en |
CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016 | MMWR |
The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC). |
| CDC | 0.59288 |
| opioid abuse | 0.571244 |
| chronic noncancer pain | 0.540474 |
| opioid dosage | 0.568503 |
| opioid tapering strategies | 0.547962 |
| contextual evidence | 0.615867 |
| opioid selection | 0.547009 |
| clinical evidence review | 0.56975 |
| higher opioid dosages | 0.558623 |
| opioid tapering protocols | 0.54297 |
| opioid treatment programs | 0.553152 |
| patients | 0.516255 |
| prescription opioid pain | 0.6245 |
| opioid rotation | 0.535118 |
| high-dose opioid therapy | 0.567724 |
| pain management | 0.543802 |
| primary care clinicians | 0.524769 |
| opioid pain medication | 0.952968 |
| opioid use disorder | 0.671382 |
| opioid management plans | 0.548114 |
| opioid tapering | 0.560301 |
| Opioid Risk Tool | 0.557406 |
| specific opioid pain | 0.614573 |
| opioid prescribing rates | 0.589318 |
| opioid dependence | 0.538082 |
|
| opioid dosages | 0.569997 |
| chronic pain | 0.808755 |
| Opioid Assessment | 0.537098 |
| daily opioid dosage | 0.545871 |
| opioid prescription | 0.619564 |
| draft guideline | 0.525989 |
| Time-scheduled opioid | 0.536675 |
| opioid overdose epidemic | 0.590396 |
| common opioid medications | 0.545779 |
| opioid prescribing recommendations | 0.55934 |
| long-term opioid treatment | 0.592325 |
| opioid prescriptions | 0.628 |
| contextual evidence review | 0.583315 |
| ER/LA opioid | 0.538516 |
| long-term opioid therapy | 0.772271 |
| immediate-release opioid | 0.537188 |
| later opioid misuse | 0.562451 |
| opioid medications | 0.589203 |
| opioid medication | 0.555155 |
| opioid dosing strategies | 0.547844 |
| opioid misuse | 0.566795 |
| primary care | 0.544848 |
| opioid pain medications | 0.634013 |
| Opioid Guideline Workgroup | 0.584925 |
|
CLICK HERE |
| 14638 |
Centers for Disease Control and Prevention |
Html |
en |
Lab Training | CDC |
CDC Laboratory Training provides contemporary professional development programs, training for timely transfer of new laboratory protocols, preemptive emergency response instruction and innovative training programs for the public health and clinical laboratory workforce. |
| Molecular Genetics Testing | 0.570618 |
| Antimicrobial Susceptibility Quality | 0.637148 |
| unknown pathogenicity protozoa | 0.55547 |
| Susceptibility Testing Methods | 0.738395 |
| rabies laboratory | 0.573955 |
| Gram Negative Organism | 0.538346 |
| Gram Positive Organism | 0.543652 |
| Learn several core | 0.547539 |
| quality control | 0.546972 |
| morphological identification | 0.575596 |
| prostate specific antigen | 0.628248 |
| molecular genetic test | 0.543558 |
| Susceptibility Testing Educational | 0.615741 |
| laboratory identification | 0.661487 |
| Basic Culture Media | 0.552136 |
| laboratory diagnosis | 0.53787 |
| Core Microbiology Skills | 0.542699 |
| laboratory professional | 0.558894 |
| HIV test technologies | 0.536342 |
| Learn basic microbiology | 0.63407 |
| Public Health Laboratory | 0.577954 |
| human intestinal tract | 0.673223 |
| Specific Antigen Testing | 0.568466 |
| human diagnostic samples | 0.536317 |
|
| Laboratory Methods | 0.570717 |
| clinical specimens | 0.539389 |
| Antimicrobial Susceptibility CLSI | 0.635862 |
| HIV Testing Technologies | 0.562243 |
| biological safety cabinet | 0.650211 |
| CDC Flu rRT-PCR | 0.64265 |
| Flu rRT-PCR Dx | 0.64049 |
| Learn antimicrobial susceptibility | 0.705572 |
| rRT-PCR Dx Panel | 0.633746 |
| Laboratory Response Network | 0.598191 |
| good laboratory practices | 0.666492 |
| antimicrobial susceptibility testing | 0.974228 |
| common laboratory contaminants | 0.59534 |
| Emerging Pathogenic Molds | 0.666137 |
| Mycobacterium tuberculosis complex | 0.551739 |
| Influenza Detection Subtyping | 0.559973 |
| bioterrorism agent identification | 0.559804 |
| Sentinel Laboratories Curriculum | 0.55578 |
| Human Entamoeba Species | 0.545841 |
| Learn diagnostic mycobacteriology | 0.629075 |
| laboratory skills | 0.539317 |
| standardized testing procedures | 0.601746 |
| Learn traditional rabies | 0.659794 |
| Basic Microbiology eLearning | 0.563877 |
|
CLICK HERE |
| 15403 |
Centers for Disease Control and Prevention |
Html |
en |
Impact of Health Insurance Expansions on Nonelderly AdultsWith Hypertension |
Preventing Chronic Disease (PCD) is a peer-reviewed electronic journal established by the National Center for Chronic Disease Prevention and Health Promotion. PCD provides an open exchange of information and knowledge among researchers, practitioners, policy makers, and others who strive to improve the health of the public through chronic disease prevention. |
| lifetime health events | 0.460049 |
| health insurance | 0.937285 |
| myocardial infarction | 0.454954 |
| systolic blood pressure | 0.511713 |
| CVD-related mortality rates | 0.43261 |
| insurance coverage | 0.854085 |
| hypertensive patients | 0.454575 |
| diastolic blood pressure | 0.435057 |
| health insurance rates | 0.501773 |
| new CVD events | 0.461577 |
| CVD prevention strategies | 0.447273 |
| insurance expansions | 0.758014 |
| CVD risk groups | 0.461735 |
| health insurance coverage | 0.673278 |
| blood pressure | 0.878988 |
| risk factors | 0.490884 |
| fewer CVD events | 0.477826 |
| cardiovascular disease risk | 0.484208 |
| insurance status | 0.515644 |
| Affordable Care Act | 0.452712 |
| American Heart Association | 0.574541 |
| CVD incidence rates | 0.482544 |
| CVD-related deaths | 0.463583 |
| antihypertensive medications | 0.550595 |
|
| health benefits | 0.512815 |
| CVD events | 0.593195 |
| health effects | 0.483484 |
| health insurance rate | 0.462786 |
| Framingham CVD risk | 0.535985 |
| CVD risk functions | 0.538331 |
| United States | 0.45084 |
| improved hypertension treatment | 0.515674 |
| Insurance coverage levels | 0.436622 |
| health insurance expansions | 0.747252 |
| fewer CHD cases | 0.442747 |
| cardiovascular disease | 0.634617 |
| hypertension treatment rates | 0.569561 |
| expansion scenario | 0.455686 |
| averted CVD events | 0.453041 |
| Health insurance status | 0.451025 |
| population-level CVD incidence | 0.444156 |
| post-ACA insurance rates | 0.433243 |
| greater health effects | 0.472595 |
| Health Insurance Marketplaces | 0.47368 |
| CVD disease | 0.431942 |
| et al | 0.573232 |
| coronary heart disease | 0.622828 |
| CVD risk factors | 0.471406 |
|
CLICK HERE |
| 15556 |
Centers for Disease Control and Prevention |
Html |
en |
What Is the National DPP? |
National Diabetes Prevention Program |
| prevention program | 0.238594 |
| lifestyle change programs | 0.869514 |
| overall health | 0.251367 |
| diabetes prevention efforts | 0.304888 |
| Prevent Diabetes STAT | 0.38602 |
| lifestyle change program | 0.374789 |
| lifestyle coach | 0.218524 |
| National DPP | 0.911561 |
| Research-Based Prevention Program | 0.22861 |
| National Diabetes Prevention | 0.333636 |
|
| online CDC-recognized lifestyle | 0.269295 |
| CDC-recognized lifestyle change | 0.4518 |
| lasting lifestyle changes | 0.282267 |
| National DPP Infographic | 0.510621 |
| online lifestyle change | 0.283756 |
| nationwide teach participants | 0.228048 |
| public awareness campaign | 0.226045 |
| American Diabetes Association | 0.282812 |
| health care providers | 0.222582 |
|
CLICK HERE |